SILO PHARMA, INC. Income (Loss) from Continuing Operations, Per Diluted Share
SILO PHARMA, INC. (SILO) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.19 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2025-03-28
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-09-30 was -$0.21.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-06-30 was -$0.32.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-03-31 was -$0.29.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2022-09-30 was -$0.49, a 115.31% decline year-over-year.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$1.19.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$1.18.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$1.71, a 219.58% decline from fiscal 2021.
- SILO PHARMA, INC. income (loss) from continuing operations, per diluted share for fiscal 2021 was $1.43.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$1.19 10-K · filed 2025-03-28 | ||||
| 2023-12-31 | -$1.18 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | -$0.21 10-Q · filed 2023-11-13 | -$0.82 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | -$0.32 10-Q · filed 2023-08-11 | -$0.61 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | -$0.29 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | -$1.71 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | -$0.49 10-Q · filed 2023-11-13 | -$1.13 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$0.33 10-Q · filed 2023-08-11 | -$0.64 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$0.31 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | $1.43 10-K · filed 2023-03-24 | $0.04 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $3.20 10-Q · filed 2022-11-10 | $1.90 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | -$0.05 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |